Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization.

@article{Klugman1996ImmunogenicityEA,
  title={Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization.},
  author={Keith P. Klugman and Hendrik J. Koornhof and John B. Robbins and N N Le Cam},
  journal={Vaccine},
  year={1996},
  volume={14 5},
  pages={435-8}
}
The protective efficacy and immunogenicity of Vi capsular polysaccharide vaccine against typhoid fever was measured 3 years after its administration in a double-blind randomized trial. Vaccine efficacy was not significantly different during each year of the trial and was 55% (95% CI: 30-71%) over the 3 year period. In a case-control study at 3 years after vaccination, recipients of Vi had higher levels of Vi antibodies than controls, as measured by radio-immunoassay (GMT 1.28 vs 0.76 microgram… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 78 extracted citations

Usefulness of the Serial Measurement of Vi Antibodies

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…